RxDoctor Payments Data

Kurt Frauenpreis, MD

Family Medicine · Dayton, WANPI 1093732182

Payments from drug & device makers

$1,292in general payments, 2019–2025

Across 89 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$287
  • AbbVie$191
  • Lilly USA, LLC$90
  • GSK$83
  • Novartis$78
  • Pfizer$77
  • plus $486 from 17 others

What the payments were for

  • Food & beverage$1,292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,292 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$61,139
Medicare patients
250
Services billed
1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$110,250
JardianceEmpagliflozin102$83,221
OzempicSemaglutide53$67,850
JanuviaSitagliptin Phosphate69$42,183
TrulicityDulaglutide30$39,602
XareltoRivaroxaban52$32,303
FarxigaDapagliflozin Propanediol34$31,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,864
EntrestoSacubitril/Valsartan30$21,285
LinzessLinaclotide29$21,242
RybelsusSemaglutide13$15,082
Tresiba Flextouch U-100Insulin Degludec33$13,500
Bydureon BciseExenatide Microspheres16$13,290
Breo ElliptaFluticasone/Vilanterol31$12,659
MyrbetriqMirabegron13$9,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$110,250193 claims
Boehringer IngelheimJardiance, Tradjenta$68$92,830121 claims
Novo NordiskOzempic, Rybelsus$287$82,93166 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$83$50,53886 claims
AstraZenecaFarxiga, Symbicort$17$39,86356 claims
Lilly USA, LLCTrulicity$90$39,60230 claims
Johnson & JohnsonXarelto$29$32,30352 claims
NovartisEntresto$78$21,28530 claims
AbbVieLinzess$191$21,24229 claims
Astellas Pharma US IncMyrbetriq$46$9,78913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Dayton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →